The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases

<table>ROC curves for the GLYCOV and CA125 markers generated using 20 primary serous early-stage EOC patients and (a) 33 healthy controls or (b) 20 patients suffering from benign ovarian diseases.</table>

Disease Markers

fig2

Figure 2

Figure 2: The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases 